Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Appili Therapeutics Inc T.APLI

Alternate Symbol(s):  APLIF

Healthcare
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. The Company’s anti... see more

Recent & Breaking News (TSX:APLI)

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

Business Wire April 2, 2024

Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.

GlobeNewswire April 2, 2024

Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks

GlobeNewswire March 12, 2024

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024

GlobeNewswire February 13, 2024

Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan

Business Wire December 15, 2023

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024

Business Wire November 13, 2023

Appili Therapeutics' Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy

Business Wire October 25, 2023

Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update

Business Wire September 27, 2023

Appili Therapeutics Presents at the 10th International Tularemia Conference

Business Wire September 27, 2023

Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ(TM) (ATI-1501) Metronidazole Oral Suspension

Business Wire September 25, 2023

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024

Business Wire August 11, 2023

Appili Therapeutics Announces Bridge Loan from Bloom Burton & Co.

Business Wire June 29, 2023

Appili Therapeutics - Press Release Correction

Business Wire June 23, 2023

Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results

Business Wire June 23, 2023

Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole

Business Wire May 24, 2023

Appili Therapeutics Secures Contract for ATI-1701 Funding from the U.S. Air Force Academy

Business Wire May 8, 2023

Appili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

Business Wire April 18, 2023

Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer

Business Wire April 3, 2023

Appili Therapeutics Announces Additional Funding of CAD$2.5 million under Non-Convertible Secured Loan with Long Zone Holdings

Business Wire March 20, 2023

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023

Business Wire February 14, 2023